H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study is the first to compare the efficacy and safety of recombinant human adenovirus
type 5 injection via hepatic artery infusion combined with TACE-based combination therapy for
the treatment of patients with stage IIIa primary hepatocellular carcinoma with portal vein
carcinoma thrombosis, providing a safe and reliable treatment method for the clinical
treatment of this group of patients, and also providing a reference and basis for the
treatment of other tumors with this new treatment model.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital